Azacitidin Stada
Azacitidin Stada is a generic from Spirig HealthCare AG and is listed on the FOPH Specialities List. Basic health insurance reimburses it within the authorised indication. The public price ranges from CHF 253.90 to CHF 347.75 depending on the pack; the co-payment is 10 per cent.
Core data
- Authorisation holder
- Spirig HealthCare AG
- ATC code
- L01BC07
- IT group
- 07.16.10 Cytostatica
- Active substances
- Azacitidinum
- Preparation type
- Generic
- On the SL since
- 01/05/2024
- Last price change
- 01/05/2024
- Co-payment
- 10%
Prices per pack
The ex-factory price is the authorisation holder's price; the public price adds the distribution share and VAT. Both are FOPH maximum prices: nothing above them may be charged.
| Dosage form | Pack size | Ex-factory price | Public price | Valid from | Cat. | GTIN |
|---|---|---|---|---|---|---|
| Trockensub 100 mg | Durchstf 1 Stk | CHF 218.38 | CHF 253.90 | 01/05/2024 | A | 7680692380012 |
| Trockensub 150 mg | Durchstf 1 Stk | CHF 304.64 | CHF 347.75 | 01/05/2024 | A | 7680692380029 |
Limitation
This preparation is reimbursed only under the conditions below. The text is the binding FOPH wording; outside those conditions basic insurance does not pay.
The FOPH publishes limitation texts in German, French and Italian only. The German wording is reproduced verbatim below.
- Myelodysplastisches Syndrom mit intermediärem oder hohem Risiko gemäss International Prognostic Scoring System (IPSS) vom Typ refraktäre Zytopenie mit multilineärer Dysplasie (RCMD) oder refraktäre Anämie mit 5-19% Knochenmarksblasten (RAEB I und II)
- Chronisch myelomonozytäre Leukämie
- Akute myeloische Leukämie (AML) mit 20-30% Knochenmarksblasten und Mehrlinien-Dysplasie (gemäss Klassifikation der World Health Organisation (WHO) 2008)
- Akute myeloische Leukämie (AML) mit >30% Knochenmarksblasten, gemäss Klassifikation der WHO, bei älteren Patienten, die für eine intensive Chemotherapie nicht geeignet sind oder diese nicht vertragen.
More preparations in this group
FAQ
Is Azacitidin Stada covered by Swiss health insurance?
Yes, but only under conditions. Azacitidin Stada is on the Specialities List with a limitation: basic insurance reimburses it only when the conditions in the limitation text are met, in some cases only after the insurer has granted cost approval.
What does Azacitidin Stada cost in Switzerland?
The public price is the maximum price set by the FOPH and for Azacitidin Stada ranges from CHF 253.90 to CHF 347.75 per pack. The ex-factory price ranges from CHF 218.38 to CHF 304.64. Pharmacies may not charge more, but may charge less.
Market access
Do you need your product on the Specialities List?
Questions about SL listing, prices or limitations? Contact Swiss Reimbursement.
- Independent directory
- Official FOPH data
- Website in eight languages